Cargando…
免疫组化法检测非小细胞肺癌EGFR突变的进展
In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response beter to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000510/ https://www.ncbi.nlm.nih.gov/pubmed/25248714 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.09.11 |